Cracking Peanuts and the Code to Wilson Disease
Warren is the first person in the world to receive a groundbreaking treatment for this rare, serious genetic condition, Wilson Disease, in which excessive amounts of copper accumulates in the body, particularly in the liver and brain. Wilson Disease can cause liver and neurological damage, as well as psychiatric issues with memory, impulse control, and anger. A strong, long-term relationship between Warren and Professor of Medicine Michael Schilsky, MD, the physician who is investigating this treatment, has been essential to this novel treatment which has the potential to help patients all over the world.
New technology could be game changer for people living with Type 1 diabetes
There's a new high-tech tool that could be a game-changer for people with Type 1 diabetes. Yale Principal Investigator and Associate Professor in Pediatrics (Endocrinology), Jennifer Sherr, discusses the Omnipod 5, which monitors insulin levels through a sensor on the skin, then sends the insulin directly through the patch as needed.Source: WNYT.com
Four Yale Researchers Honored at the 2022 Association for Clinical and Translational Science Awards
The collaboration that advanced the discovery of ketamine as a treatment for depression was among four Yale award winners at the Association for Clinical and Translational Science (ACTS) annual meeting held in Chicago from April 20 through 22.
Linda Coleman accepts appointment to the Board of Directors, Association for the Accreditation of Human Research Protection Programs
Linda Coleman, JD, the Director of the Yale Human Research Protection Program (HRPP), which assists Yale University in meeting its ethical and regulatory obligations for the protection of human research participants, has accepted an appointment to the Board of Directors of the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
YCCI’s Tesheia Johnson Appointed to CTSA Steering Committee
The National Center for Advancing Translational Sciences (NCATS) has announced the new members of its Clinical and Translational Science Awards (CTSA) Program steering committee, including Yale School of Medicine Director of Clinical Research and Yale Center for Clinical Investigation (YCCI) Chief Operating Officer Tesheia Johnson, MBA, MHS. The steering committee provides direction to NCATS and the more than 60 CTSA-funded institutions around the country, including Yale.
Yale doctor on CT’s positivity rate nearing 5%, latest research on Moderna’s vaccine, unvaccinated discouraged from Labor Day travel
Yale Infectious Disease expert, Dr. Onyema Ogbuagu discusses CT’s positivity rate nearing 5%, latest research on Moderna’s vaccine, unvaccinated discouraged from Labor Day travelSource: WTNH
Herold is New Chair of International Diabetes Consortium
Kevan C. Herold, MD, C.N.H. Long Professor of Immunobiology and professor of medicine (endocrinology) at Yale School of Medicine, has been named chair of Type 1 Diabetes (T1D) TrialNet, an international consortium dedicated to finding ways to prevent, delay, and slow progression of the disease.
Waterbury Black church leaders, Yale team up to dispel myths about COVID vaccine for communities of color, seniors
In Waterbury, an aggressive effort to take the COVID-19 vaccine to hard-to-reach communities embarked on another chapter Friday. This time, one of the city’s most popular Black churches engaged in something unique to shatter some vaccine myths.Source: WTNH
Strategies to accelerate diagnosis and treatment of rare cardiovascular diseases
The current landscape for patients with rare cardiovascular disease has shifted. Using genome sequencing Yale physician-scientists have begun to elucidate the pathophysiology of genetic disorders and develop treatment guidelines and recommendations.
Yale-led Clinical Trial Offers Hope for COVID Patients and a Path Forward for Research
A new randomized study could reduce the morbidity and mortality associated with COVID-19 and streamline clinical research at Yale. The study will enroll 466 patients across five different Yale New Haven Hospital sites to identify a potential COVID-19 treatment.